BI
RNAC icon

BVF Inc’s Cartesian Therapeutics RNAC Stock Holding History

BVF Inc’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46,392
Closed -$1.57M – 78
2022
Q4 		$1.57M Hold
46,392
– – 0.07% 69
2022
Q3 		$2.28M Sell
46,392
-11,046
-19% -$607K 0.09% 67
2022
Q2 		$2.26M Hold
57,438
– – 0.11% 67
2022
Q1 		$2.12M Hold
57,438
– – 0.08% 76
2021
Q4 		$5.62M Buy
57,438
+46,782
+439% +$5.03M 0.2% 63
2021
Q3 		$1.33M Sell
10,656
-45,793
-81% -$5.53M 0.05% 75
2021
Q2 		$7.08M Sell
56,449
-22,884
-29% -$2.73M 0.27% 55
2021
Q1 		$10.8M Sell
79,333
-30,832
-28% -$3.83M 0.4% 47
2020
Q4 		$10M Sell
110,165
-171,820
-61% -$14.9M 0.39% 45
2020
Q3 		$21M Buy
281,985
+5,500
+2% +$421K 1.14% 29
2020
Q2 		$23.6M Buy
276,485
+156,169
+130% +$14.2M 1.45% 26
2020
Q1 		$8.7M Buy
120,316
+10,847
+10% +$1.05M 0.81% 30
2019
Q4 		$7.82M Buy
+109,469
New +$5.28M 0.59% 36

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BVF Inc's RNAC Position: Q1 2023 in Review

BVF Inc sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 46,392 shares — an estimated $1.57M sold.

BVF Inc first reported a position in RNAC in Q4 2019 and held it in 13 quarters. The position peaked at $23.6M in Q2 2020. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • BVF Inc reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • BVF Inc sold 46,392 Cartesian Therapeutics shares in Q1 2023, an estimated $1.57M.
  • BVF Inc first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 13 quarters.
  • BVF Inc's Cartesian Therapeutics position peaked at $23.6M in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on BVF Inc's 13F filing for Q1 2023, filed 15 May 2023.